Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 7/20 | 0.47 |
| ▸ | FNTA | P49354 | 4/20 | 0.40 |
| ▸ | FNTB | P49356 | 4/20 | 0.40 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RRM1 | P23921 | 1/20 | 0.37 |
| ▸ | F7 | P08709 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14090782 | 1.00 | C3AR1 (0.47) | C3AR1FNTAFNTBPGGT1BLMNA | |
| SCHEMBL14091183 | 0.90 | C3AR1 (0.43) | C3AR1FNTAFNTBPGGT1BLMNA | |
| SCHEMBL6801475 | 0.83 | CNR1 (0.48) | C3AR1FNTAFNTBPGGT1BLMNA | |
| SCHEMBL6801482 | 0.83 | CNR1 (0.48) | C3AR1FNTAFNTBPGGT1BLMNA | |
| SCHEMBL4552682 | 0.79 | FOLH1 (0.40) | C3AR1FOLH1MEN1KMT2A | |
| SCHEMBL1724846 | 0.79 | FOLH1 (0.40) | C3AR1FOLH1MEN1KMT2A | |
| SCHEMBL14090878 | 0.79 | NPSR1 (0.50) | MEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL31184339 | 0.78 | FOLH1 (0.39) | C3AR1FOLH1MEN1KMT2A | |
| SCHEMBL29697124 | 0.78 | C3AR1 (0.52) | C3AR1FNTAFNTBPGGT1BFOLH1 | |
| SCHEMBL6801489 | 0.78 | C3AR1 (0.61) | C3AR1FNTAFNTBPGGT1BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125739-A1 | MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| WO-2008079371-A1 | MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | C3AR1, C5, C5AR1 | C3AR1 1/4885FNTA 863/4885FNTB 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.